Vancomycin dry powder inhalation - Savara Pharmaceuticals
Alternative Names: AeroVanc; Vancomycin hydrochloride inhalation powderLatest Information Update: 02 Dec 2021
At a glance
- Originator Savara Pharmaceuticals
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Methicillin-resistant Staphylococcus aureus infections
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 10 Dec 2020 Discontinued - Phase-I for Methicillin-resistant Staphylococcus aureus infections in Australia (Inhalation)
- 10 Dec 2020 Discontinued - Phase-III for Methicillin-resistant Staphylococcus aureus infections (In adolescents, In children, In the elderly, In adults) in Canada (Inhalation)
- 10 Dec 2020 Discontinued - Phase-III for Methicillin-resistant Staphylococcus aureus infections (In adolescents, In children, In the elderly, In adults) in USA (Inhalation)